Summary
Mortality due to vaginal or intravenous infection of female BALB/c mice with herpes simplex virus type 2 (HSV-2) was significantly reduced by treatment of mice with the immunomodulator pyran. Following intravaginal inoculation with virus, the incidence of vaginal infection and titers of virus present in the vaginal secretions were significantly reduced in pyran treated as compared with control mice. Vaginal infection did not elicit neutralizing antibody activity in either untreated or pyran treated mice. Intravenous HSV-2 infection did elicit virus specific humoral and delayed type hypersensitivity responses. However, pyran treatment markedly reduced the incidence of these immune responses as compared with those in control intravenously infected mice. Moreover, mice surviving the initial vaginal or intravenous infection with HSV-2 were resistant to subsequent rechallenge by the same route. Pyran treatment did not enhance resistance to vaginal rechallenge, while pyran treated mice were not resistant to intravenous rechallenge. Thus, the antiviral protection mediated by pyran does not appear to involve enhancement of specific humoral or cellular immune responses. Nonspecific host mediated resistance may be involved in the protective effect of the immunomodulator, as suggested by the ability of pyran activated peritoneal cells to inhibit HSV-2 growthin vitro and to transfer resistance to recipient mice challenged with the virus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams, H. G., Benson, E. A., Alexander, E. R., Vontver, L. A., Remington, M. A., Holmes, K. K.: Genital herpetic infection in men and women: clinical course and effect of topical application of adenine arabinoside. J. inf. Dis.133, 151–159 (1976).
Allen, L. B., Hintz, C. J., Wolf, S. M., Huffman, H. J., Simon, L. N., Robins, R. K., Sidwell, R. W.: Effect of 9-B-D-arabinofuranosylhypoxanthine 5′-monophosphate on genital lesions and encephalitis induced by herpesvirus hominis type 2 in female mice. J. inf. Dis.133, A178–183 (1976).
Anderson, F. D., Ushijima, R. N., Larson, C. L.: Recurrent herpes genitalis. Treatment with mycobacterium bovis (BCG). Obstet. Gynecol.43, 797–805 (1974).
Baird, L. G., Kaplan, A. M.: Immunoadjuvant activity of pyran copolymer. I. Evidence for direct stimulation of T-lymphocytes and macrophages. Cell. Immunol.20, 167–176 (1975).
Baker, M. B., Larson, C. L., Ushijima, R. N., Anderson, F. D.: Resistance of female mice to vaginal infection induced by herpesvirus hominis type 2: Effects of immunization with mycobacterium bovis, intravenous injection of a specific herpesvirus hominis type 2 antiserum, and a combination of these procedures. Infect. Immun.10, 1230–1234 (1974).
Billiau, A., Muyembe, J. J., DeSomer, P.: Mechanism of antiviral activity of polycarboxylates which induce interferon. Nature (London)232, 183–186 (1971).
Boone, C. W., Paranjpe, M. S.: Delayed hypersensitivity to simian virus 40 tumor cells in Balb/c mice demonstrated by a radioisotopic footpad assay. J. Nat. Cancer Inst.48, 563–566 (1972).
Braun, W., Regelson, W., Yajima, Y., Ishizuka, M.: Stimulation of antibody formation by pyran copolymer. Proc. Soc. exp. Biol. Med.131, 171–175 (1970).
Burns, W. H., Billups, L. C., Notkins, A. L.: Thymus dependence of viral antigens. Nature (London)256, 654–655 (1975).
DeClercq, E., Luczak, M.: Antiviral activity of carbopol, a cross-linked polycarboxylate. Arch. Virol.52, 151–158 (1976).
DeClercq, E., Merigan, T. C.: Local and systemic polyanionic interferon inducers in mice against intranasal vesicular stomatitis virus. J. gen. Virol.5, 359–368 (1969).
Goodman, E. L., Luby, J. P., Johnson, M. T.: Prospective doubleblind evaluation of topical adenine arabinoside in male herpes progenitalis. Antimicrob. Agents Chemother.8, 693–697 (1975).
Hirsch, M. S., Zisman, B., Allison, A. C.: Macrophages and agedependent resistance to herpes simplex virus in mice. J. Immunol.104, 1160–1165 (1970).
Kaplan, A. M., Morahan, P. S., Regelson, W.: Induction of macrophage-mediated tumor-cell cytotoxicity by pyran copolymer. J. Natl. Cancer Inst.52, 1919–1923 (1974).
Kaplan, A. M., Walker, P. L., Morahan, P. S.: Tumor cell cytotoxicity versus cytostatis of pyran-activated macrophages. In:Chirigos, M. (ed.), Modulation of host immune resistance in prevention and treatment of neoplasia, 277–286. Fogarty International Center Proceedings 28, U.S. Government Printing Office. 1977.
Kern, E. R., Richards, J. T., Overall, J. C., Jr., Glasgow, L. A.: Genital herpesvirus hominis infection in mice. II. Treatment with phosphonoacetic acid, adenine arabinoside, and adenine arabinoside 5′-monophosphate. J. inf. Dis.135, 557–567 (1977).
Larson, C. L., Ushijima, R. N., Karin, R., Baker, M. B., Baker, R. E.: Herpesvirus hominis type 2 infections in rabbits. Effect of prior immunization with attenuated mycobacterium bovis (BCG) cells. Infect. Immun.6, 465–468 (1972).
McCord, R. S., Breinig, M. K., Morahan, P. S.: Antiviral effect of pyran against systemic infection of mice with herpes simplex virus type 2. Antimicrob. Ag. Chemother.10, 28–33 (1976).
Morahan, P. S., Glasgow, L. A., Crane, J. L., Jr., Kern, E. R.: Comparison of antiviral and antitumor activity of activated macrophages. Cell. Immunol.28, 404–415 (1977).
Morahan, P. S., Kern, E. R., Glasgow, L. A.: Immunomodulator-induced resistance against herpes simplex virus. Proc. Soc. exp. Biol. Med.154, 615–620 (1977).
Morahan, P. S., McCord, R. S.: Resistance to herpes simplex type 2 virus induced by an immunopotentiator (pyran) in immunosuppressed mice. J. Immunol.115, 311–313 (1975).
Morahan, P. S., Regelson, W., Munson, A. F.: Pyran and polyribonucleotides: Differences in biological activities. Antimicrob. Ag. Chemother.2, 16–22 (1972).
Nahmias, A. J., Josey, W. E., Naib, Z. M., Visintine, A. M.: Genital herpetic infection—the old and the new. In:Cotterall andNicol (eds.), Sexually Transmitted Diseases, 136–151. New York: Academic Press 1976.
Overall, J. C., Jr., Kern, E. R., Schlitzer, R. L., Friedman, S. B., Glasgow, L. A.: Genital herpesvirus hominis infection in mice. I. Development of an experimental model. Infect. Immun.11, 476–480 (1975).
Regelson, W., Munson, A. E.: The reticuloendothelial effects of interferon inducers: Polyanionic and non-polyanionic phylaxis against microorganisms. Ann. N.Y. Acad. Sci.173, 831–841 (1970).
Schuller, G. B., Morahan, P. S.: Cellular and serum involvement in protection against Friend leukemia virus. Cancer Res. (in press, 1977).
Yam, L. T., Li, C. Y., Crosby, W. H.: Cytochemical identification of monocytes and granulocytes. Amer. J. clin. Pathol.55, 283–290 (1971).
Author information
Authors and Affiliations
Additional information
With 1 Figure
Rights and permissions
About this article
Cite this article
Breinig, M.C., Wright, L.L., McGeorge, M.B. et al. Resistance to vaginal or systemic infection with herpes simplex virus type 2. Archives of Virology 57, 25–34 (1978). https://doi.org/10.1007/BF01315634
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01315634